[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-ataxia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-ataxia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100608357","telerehabilitation-for-core-stability-and-strength-in-hereditary-ataxia-100608357",false,"NCT07200505","Telerehabilitation for Core Stability and Strength in Hereditary Ataxia","A Telerehabilitation Intervention Targeting Core Stability and Muscular Strength in Individuals With Moderate-to-Advanced Hereditary Ataxia: A Pilot Study","TRCORE-AH2","Inclusion Criteria:\n\n* Confirmed diagnosis of spinocerebellar hereditary ataxia.\n* Moderate severity defined by the SARA scale (10-20 points, Traschütz et al., 2023).\n* Stable internet access and suitable electronic devices.\n\n  * Basic digital literacy.\n  * Signed informed consent.\n\nExclusion Criteria:\n\n* Mild (\\\u003C10) or severe (\\>20) scores on the SARA scale.\n* Severe comorbidities preventing safe exercise participation.\n* Severe cognitive impairment that would preclude program adherence.","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a two-arm, controlled clinical trial with a parallel design. Participants will be randomly assigned to an intervention or control group. The study is single-blind, as outcome assessors will be blinded to group allocation, while participants and physiotherapists cannot be blinded due to the nature of the intervention. Consecutive sampling will be applied.\n\nFor the evaluation of intervention effects (primary and secondary outcomes), the study will follow the Consolidated Standards of Reporting Trials (CONSORT) for non-pharmacological interventions. For the assessment of satisfaction and adherence, a qualitative study will be conducted following the COREQ EQUATOR 17 guidelines to ensure methodological rigor.\n\nThe intervention will consist of a 12-week home-based exercise program supervised via mixed telerehabilitation (TR). The control group will perform the same program but receive only telephone follow-up. Four assessments will be conducted: baseline (T0), post-intervention (T1), three months follow-up (T2), and six months follow-up (T3).",[27],"Hereditary Ataxia","NOT_YET_RECRUITING","2025-09-26",{"date":31,"type":32},"2025-10-01","ACTUAL",{"date":34,"type":21},"2026-02-09",{"date":36,"type":21},"2026-12-21",{"name":38,"class":39},"Universitat de Lleida","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100600043","hereditary-ataxia-research-on-multi-omics-and-neuroclinical-insights-in-the-yangtze-delta-100600043","NCT07092358","Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta","HARMONY","Inclusion Criteria:\n\n* Presence of progressive ataxia as a primary or persistent clinical feature;\n* Sufficient evidence to exclude acquired causes of ataxia (e.g., chronic intoxication, immune-mediated inflammation, acquired vitamin deficiency, acute injury, stroke, infection, or space-occupying disorders);\n* For sporadic late-onset cases (≥30 years), disease duration must exceed 3 years, with no prominent progressive autonomic dysfunction or other features indicative of multiple system atrophy-cerebellar type (MSA-C);\n* Ability and willingness of the participant or legal guardian to provide informed consent and complete the entire study process.\n\nExclusion Criteria:\n\n* Patients whose causative genes identified through genetic testing and analysis do not fall within the defined spectrum of hereditary ataxias, based on consensus classifications from the MDS Task Force on Genetic Movement Disorders and the SRCA Working Group, along with current research advancements;\n* Presence of concurrent cerebrovascular disease, brain tumors, or severe systemic illness;\n* Refusal to sign informed consent or provide biological samples by the participant or legal representative;\n* Inability or unwillingness to participate in follow-up assessments.",{"count":49,"type":21},5000,"10 Years","OBSERVATIONAL","The goal of this observational study is to explore the clinical and genetic characteristics, multi-omics profiles, disease mechanisms, biomarkers, and potential therapeutic targets of hereditary ataxia (HA) in patients diagnosed with HA, primarily in the Yangtze River Delta region of China. The main questions it aims to answer are:\n\n* What are the key pathogenic genetic variants, modifying factors and special inheritance patterns underlying HA?\n* How do multi-omics profiles correlate with clinical phenotypes, disease progress and mechanism in HA patients?\n* What are the implications of these findings for clinical practice?\n\nParticipants will:\n\n* Undergo retrospective and prospective clinical data collection through long-term follow-up to observe disease onset, progression, and outcomes.\n* Provide biological samples (e.g., blood, skin) to establish a biobank for multi-omics analyses.\n* Be characterized using multidimensional omics technologies to identify disease-related molecular signatures, progression mechanisms, and potential regulatory targets.",[27],[55,56],"multiomics","clinical and genetic characteristics","RECRUITING","2025-07-22",{"date":60,"type":32},"2025-07-29",{"date":62,"type":32},"2025-06-01",{"date":64,"type":21},"2035-12-31",{"name":66,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]